

HUNTINGTON'S DISEASE SOCIETY  
OF AMERICA, INC.

FINANCIAL STATEMENTS

DECEMBER 31, 2025 and 2024

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Contents

	<b><u>Page</u></b>
<b>Independent Auditors' Report</b>	1 - 2
<b>Financial Statements</b>	
Statements of financial position as of December 31, 2025 and 2024	3
Statements of activities for the years ended December 31, 2025 and 2024	4
Statement of functional expenses for the year ended December 31, 2025 (with summarized financial information for 2024)	5
Statement of functional expenses for the year ended December 31, 2024	6
Statements of cash flows for the years ended December 31, 2025 and 2024	7
Notes to financial statements	8 - 19

## **INDEPENDENT AUDITORS' REPORT**

Board of Trustees  
Huntington's Disease Society of America, Inc.

### **Report on the Audit of the Financial Statements**

#### ***Opinion***

We have audited the financial statements of Huntington's Disease Society of America, Inc. (the "Society"), which comprise the statements of financial position as of December 31, 2025 and 2024, and the related statements of activities, functional expenses, and cash flows for each of the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Huntington's Disease Society of America, Inc. as of December 31, 2025 and 2024, and the changes in its net assets and its cash flows for each of the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### ***Basis for Opinion***

We conducted our audits in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Society and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### ***Responsibilities of Management for the Financial Statements***

The Society's management is responsible for the preparation and fair presentation of these financial statements, in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Society's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

## ***Auditors' Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Society's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Society's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

*EisnerAmper LLP*

EISNERAMPER LLP  
New York, New York  
April 17, 2026



# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Statements of Financial Position

	December 31,	
	2025	2024
<b>ASSETS</b>		
Cash and cash equivalents	\$ 7,230,595	\$ 7,409,235
Pledges and contributions receivable, net	2,224,412	1,567,241
Investments	6,744,523	5,503,140
Prepaid expenses and deposits	267,591	251,907
Right-of-use asset	2,197,174	2,425,693
Property and equipment, net	130,665	162,905
Website and software costs, net	2,583	545,761
	<b>18,797,543</b>	<b>17,865,882</b>
<b>LIABILITIES AND NET ASSETS</b>		
Liabilities:		
Accounts payable and accrued expenses	\$ 127,654	\$ 139,416
Accrued compensation	194,259	262,658
Grants payable, net	929,705	1,747,581
Event revenue received in advance	30,053	22,336
Lease liability	2,262,114	2,463,171
	<b>3,543,785</b>	<b>4,635,162</b>
Lease agreements and commitments (see Note L)		
Net Assets:		
Without donor restrictions:		
Undesignated	9,284,655	6,337,546
Board-operating reserve	3,558,873	3,440,366
	<b>12,843,528</b>	<b>9,777,912</b>
With donor restrictions:		
Purpose restriction	1,999,703	2,925,306
Time-restricted for future periods	160,527	277,502
Perpetual in nature	250,000	250,000
	<b>2,410,230</b>	<b>3,452,808</b>
	<b>15,253,758</b>	<b>13,230,720</b>
	<b>\$ 18,797,543</b>	<b>\$ 17,865,882</b>

See notes to financial statements.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Statements of Activities

	Year Ended December 31,					
	2025			2024		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
<b>Support and revenue:</b>						
Public donations	\$ 5,891,607	\$ 249,222	\$ 6,140,829	\$ 3,370,051	\$ 526,193	\$ 3,896,244
Foundation grants and corporate contributions	1,418,073	372,260	1,790,333	1,537,876	811,206	2,349,082
Federal campaign	249,151	-	249,151	179,272	-	179,272
Special events (net of direct benefits to donors \$628,313 and \$575,126 in 2025 and 2024, respectively)	4,260,516	-	4,260,516	3,711,403	-	3,711,403
Investment earnings, net	254,989	17,326	272,315	194,012	4,723	198,735
Donated services and materials	362,673	-	362,673	205,833	-	205,833
Other income	58,903	-	58,903	32,773	-	32,773
Total support and revenue before net assets released from restrictions	12,495,912	638,808	13,134,720	9,231,220	1,342,122	10,573,342
Net assets released from restrictions	1,681,386	(1,681,386)	-	1,910,006	(1,910,006)	-
Total support and revenue	14,177,298	(1,042,578)	13,134,720	11,141,226	(567,884)	10,573,342
<b>Expenses:</b>						
Program services:						
Research	1,178,929	-	1,178,929	2,501,568	-	2,501,568
Family services	3,590,643	-	3,590,643	3,581,972	-	3,581,972
Education	2,281,814	-	2,281,814	2,036,134	-	2,036,134
Community outreach	1,084,117	-	1,084,117	938,029	-	938,029
Total program services	8,135,503	-	8,135,503	9,057,703	-	9,057,703
Supporting services:						
Management and general	974,263	-	974,263	920,055	-	920,055
Fundraising	1,545,812	-	1,545,812	2,208,668	-	2,208,668
Total supporting services	2,520,075	-	2,520,075	3,128,723	-	3,128,723
Total expenses	10,655,578	-	10,655,578	12,186,426	-	12,186,426
<b>Change in net assets before loss on disposal of website costs and returned grant funds:</b>	3,521,720	(1,042,578)	2,479,142	(1,045,200)	(567,884)	(1,613,084)
Loss on disposal of website costs	(543,595)	-	(543,595)	-	-	-
Returned grant funds	87,491	-	87,491	113,657	-	113,657
<b>Change in net assets</b>	3,065,616	(1,042,578)	2,023,038	(931,543)	(567,884)	(1,499,427)
Net assets, beginning of year	9,777,912	3,452,808	13,230,720	10,709,455	4,020,692	14,730,147
<b>Net assets, end of year</b>	\$ 12,843,528	\$ 2,410,230	\$ 15,253,758	\$ 9,777,912	\$ 3,452,808	\$ 13,230,720

See notes to financial statements.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Statement of Functional Expenses Year Ended December 31, 2025

(with summarized financial information for 2024)

	Program Services				Supporting Services			Total		
	Research	Family Services	Education	Community Outreach	Total Program Services	Management and General	Fund-raising	Total Supporting Services	2025	2024
<b>Salaries and related expenses:</b>										
Salaries	\$ 421,986	\$ 540,994	\$ 620,708	\$ 630,790	\$ 2,214,478	\$ 373,591	\$ 593,870	\$ 967,461	\$ 3,181,939	\$ 3,315,477
Payroll taxes and employee benefits	122,170	156,629	179,704	182,622	641,125	107,985	171,933	279,918	921,043	980,059
Total salaries and related expenses	544,156	697,623	800,412	813,412	2,855,603	481,576	765,803	1,247,379	4,102,982	4,295,536
<b>Other expenses:</b>										
Research grants and other awards	406,772	1,862,900	55,795	-	2,325,467	-	-	-	2,325,467	3,384,695
Office supplies	3,018	5,774	25,975	6,994	41,761	1,790	8,279	10,069	51,830	65,550
Telephone	3,873	27,830	5,209	4,813	41,725	1,712	4,913	6,625	48,350	50,245
Postage and shipping	1,765	5,671	14,882	6,983	29,301	3,031	74,349	77,380	106,681	105,206
Rent and occupancy charges	56,150	117,868	74,066	63,930	312,014	24,819	71,321	96,140	408,154	363,712
Technology and software	20,119	52,946	15,178	6,498	94,741	21,953	17,504	39,457	134,198	638,402
Printing and publications	14,509	23,429	63,880	18,124	119,942	226	88,566	88,792	208,734	279,291
Conferences, meetings and travel	12,996	74,062	718,849	10,822	816,729	5,798	59,125	64,923	881,652	894,949
Insurance	8,383	17,518	11,283	5,260	42,444	3,705	11,177	14,882	57,326	76,299
Prizes and gifts	-	1,186	3,915	117,989	123,090	-	-	-	123,090	133,566
Professional services	93,664	673,794	311,474	17,504	1,096,436	179,464	128,138	307,602	1,404,038	1,071,884
Equipment rental	6,412	12,656	122,041	1,863	142,972	1,314	3,771	5,085	148,057	67,305
Donated legal, space and auction items	-	-	7,962	3,840	11,802	208,588	142,283	350,871	362,673	205,833
Bank and credit card fees	190	883	5,238	242	6,553	2,650	105,487	108,137	114,690	121,100
Catering and venue costs	-	-	-	-	-	-	628,313	628,313	628,313	575,126
Depreciation and amortization	5,066	10,516	6,683	3,475	25,740	2,239	6,843	9,082	34,822	312,766
Other	1,856	5,987	38,972	2,368	49,183	35,398	58,253	93,651	142,834	120,087
Total expenses	1,178,929	3,590,643	2,281,814	1,084,117	8,135,503	974,263	2,174,125	3,148,388	11,283,891	12,761,552
Less: direct benefits to donors	-	-	-	-	-	-	(628,313)	(628,313)	(628,313)	(575,126)
Total expenses per statements of activities	\$ 1,178,929	\$ 3,590,643	\$ 2,281,814	\$ 1,084,117	\$ 8,135,503	\$ 974,263	\$ 1,545,812	\$ 2,520,075	\$ 10,655,578	\$ 12,186,426

See notes to financial statements.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Statement of Functional Expenses Year Ended December 31, 2024

	Program Services				Total Program Services	Supporting Services			Total
	Research	Family Services	Education	Community Outreach		Management and General	Fund- raising	Total Supporting Services	
<b>Salaries and related expenses:</b>									
Salaries	\$ 289,209	\$ 428,266	\$ 538,311	\$ 527,480	\$ 1,783,266	\$ 376,431	\$ 1,155,780	\$ 1,532,211	\$ 3,315,477
Payroll taxes and employee benefits	85,490	126,595	159,125	155,923	527,133	111,274	341,652	452,926	980,059
Total salaries and related expenses	374,699	554,861	697,436	683,403	2,310,399	487,705	1,497,432	1,985,137	4,295,536
<b>Other expenses:</b>									
Research grants and other awards	1,124,976	2,111,861	147,858	-	3,384,695	-	-	-	3,384,695
Office supplies	5,453	10,094	26,618	7,449	49,614	3,582	12,354	15,936	65,550
Telephone	8,914	14,317	7,256	6,312	36,799	3,343	10,103	13,446	50,245
Postage and shipping	697	1,676	21,145	6,533	30,051	2,258	72,897	75,155	105,206
Rent and occupancy charges	57,705	84,432	46,969	51,142	240,248	55,769	67,695	123,464	363,712
Technology and software	513,212	45,783	15,155	5,202	579,352	33,577	25,473	59,050	638,402
Printing and publications	14,450	45,803	96,956	19,419	176,628	2,352	100,311	102,663	279,291
Conferences, meetings and travel	18,874	100,120	672,866	19,234	811,094	19,296	64,559	83,855	894,949
Insurance	12,883	18,821	10,486	4,843	47,033	14,605	14,661	29,266	76,299
Prizes and gifts	323	2,553	3,315	118,782	124,973	119	8,474	8,593	133,566
Professional services	59,814	563,829	204,732	4,646	833,021	230,850	8,013	238,863	1,071,884
Equipment rental	6,509	9,796	38,697	2,443	57,445	2,484	7,376	9,860	67,305
Donated legal, space and auction items	-	1,742	6,030	3,840	11,612	7,583	186,638	194,221	205,833
Bank and credit card fees	239	686	3,917	249	5,091	2,568	113,441	116,009	121,100
Catering and venue costs	-	-	-	-	-	-	575,126	575,126	575,126
Depreciation and amortization	283,209	10,163	5,777	2,963	302,112	2,610	8,044	10,654	312,766
Other	19,611	5,435	30,921	1,569	57,536	51,354	11,197	62,551	120,087
Total expenses	2,501,568	3,581,972	2,036,134	938,029	9,057,703	920,055	2,783,794	3,703,849	12,761,552
Less: direct benefits to donors	-	-	-	-	-	-	(575,126)	(575,126)	(575,126)
Total expenses per statements of activities	<u>\$ 2,501,568</u>	<u>\$ 3,581,972</u>	<u>\$ 2,036,134</u>	<u>\$ 938,029</u>	<u>\$ 9,057,703</u>	<u>\$ 920,055</u>	<u>\$ 2,208,668</u>	<u>\$ 3,128,723</u>	<u>\$ 12,186,426</u>

See notes to financial statements.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Statements of Cash Flows

	Year Ended December 31,	
	2025	2024
<b>Cash flows from operating activities:</b>		
Change in net assets	\$ 2,023,038	\$ (1,499,427)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Depreciation and amortization	34,822	312,766
Loss on disposal of website costs	543,595	-
Bad debt expense	27,996	30,797
Noncash lease amortization	228,519	220,379
Net realized and unrealized gains on investments	(77,092)	(70,234)
Donated securities	(966,271)	(258,875)
Proceeds from sale of donated securities	966,271	130,108
Changes in:		
Pledges and contributions receivable, net	(685,167)	(645,548)
Prepaid expenses and deposits	(15,684)	125,232
Accounts payable and accrued expenses	(11,762)	(66,765)
Accrued compensation	(68,399)	(4,777)
Grants payable, net	(817,876)	594,907
Event revenue received in advance	7,717	(10,013)
Lease liability	(201,057)	(185,830)
Net cash provided by (used in) operating activities	<u>988,650</u>	<u>(1,327,280)</u>
<b>Cash flows from investing activities:</b>		
Proceeds from sales of investments	1,741,926	889,741
Purchases of investments	(2,906,217)	(450,977)
Capitalized website and software costs	(2,999)	(250,000)
Purchases of property and equipment	-	(5,175)
Net cash (used in) provided by investing activities	<u>(1,167,290)</u>	<u>183,589</u>
<b>Decrease in cash and cash equivalents</b>	<b>(178,640)</b>	<b>(1,143,691)</b>
Cash and cash equivalents, beginning of year	<u>7,409,235</u>	<u>8,552,926</u>
<b>Cash and cash equivalents, end of year</b>	<b>\$ 7,230,595</b>	<b>\$ 7,409,235</b>
<b>Supplemental disclosures of cash flow information:</b>		
Donated services and materials	<u>\$ 362,673</u>	<u>\$ 205,833</u>

See notes to financial statements.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Notes to Financial Statements December 31, 2025 and 2024

### NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### [1] The Society:

Huntington's Disease Society of America, Inc. (the "Society") was incorporated in New York in 1986. The Society is a national, voluntary health and welfare organization dedicated to improving the lives of people with Huntington's Disease ("HD") and their families. Currently, the Society has 35 chapters throughout the United States. Each chapter, staffed entirely by volunteers: (i) holds educational events, coordinates social workers, and runs support groups for local families with HD; (ii) raises funds through events (walk-a-thons, dinners, golf tournaments, and other activities) that are used to support the Society's programs of research, care and education; and (iii) strives to build greater awareness of HD in the general public through outreach to local press and civic groups.

The Society is exempt from federal income taxes pursuant to Section 501(c)(3) of the U.S. Internal Revenue Code (the "Code") and from state and local taxes under comparable laws.

#### [2] Basis of accounting:

The financial statements of the Society have been prepared using the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America ("U.S. GAAP"), as applicable to not-for-profit organizations.

#### [3] Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, support, and revenues and expenses, as well as the disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

#### [4] Cash and cash equivalents:

The Society considers all highly liquid investments, with maturities of three months or less when purchased, to be cash equivalents. Cash and cash equivalents are considered to be part of the Society's investment portfolio and are reported as investments in the statements of financial position.

#### [5] Investments:

The Society's investments in common stock, equity and fixed-income mutual funds, and U.S. Treasury bills are reported at their fair values in the statements of financial position based on quoted market prices. Cash and cash equivalents held as part of the Society's investment portfolio are also included in the balances reported as investments.

The Society's investments, in general, are subject to various risks, such as interest-rate, market, and credit risks. Due to the level of risk associated with certain investment vehicles, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

Investment transactions are recorded on a trade-date basis. Realized gains and losses on investments sold, and unrealized appreciation and depreciation on investments held, are reported in the statements of activities as increases or decreases in net assets without donor restriction unless their use is restricted through donor stipulation. Realized gains and losses on investments are determined by comparison of the cost of acquisition to proceeds at the time of disposition. Unrealized gains and losses on investments are determined by comparing the investment's cost to the fair value at the end of each year. The earnings from dividends and interest are recognized when earned.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Notes to Financial Statements December 31, 2025 and 2024

### NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### [5] Investments: (continued)

Donated securities are recorded at their estimated fair values, or by their net asset values as determined by the Society's management, on the dates of donation. The Society's policy is to sell the donated securities immediately and, accordingly, for purposes of the statements of cash flows, donated securities and the proceeds generated from their sale are included within operating activities.

Investment expenses include the service fees and costs of bank trustees, investment managers and custodians. The balances of investment management fees disclosed in Note C are those specific fees charged by the Society's various investment managers in each year; however, they do not include those fees that are embedded in various other investment accounts and transactions.

#### [6] Property and equipment:

Property and equipment are stated at their original costs at the dates of acquisition or, if contributed, at their estimated fair values at the dates of donation, less accumulated depreciation and amortization. The Society capitalizes items of property and equipment that have a cost of \$1,500 or more and a useful life greater than one year, whereas minor costs of repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over five to ten years, the estimated useful lives of computers and equipment and furniture and fixtures. Leasehold improvements are amortized over the remaining lease term, or the useful lives of the improvements, whichever is shorter.

Management evaluates the recoverability of the investment in long-lived assets on an ongoing basis and when triggering events indicate that the fair value of the long-lived assets may be less than the carrying value, recognizes any impairment in the year of determination. It is reasonably possible that relevant conditions could change in the near term and necessitate a change in management's estimate of the recoverability of these assets.

#### [7] Website and software costs:

Website and software costs related to data consulting services, site configuration and infrastructure, and conceptual design are capitalized. Costs relating to operating and content are expensed as incurred. The Society capitalizes website and software costs that have a cost of \$1,500 or more and a useful life greater than one year. Capitalized costs are amortized over a three-year expected life using the straight-line method. At December 31, 2025 and 2024, capitalized website and software costs were presented net of accumulated amortization of \$2,583 and \$545,761, respectively. During 2025, the Society retired amortized website costs no longer being utilized of \$451,402, this resulted in a loss on disposal of website costs of \$543,595.

#### [8] Accrued vacation:

Accrued vacation represents the Society's obligation for the cost of unused employee vacation time that would be payable in the event that all employees left the Society. As of December 31, 2025 and 2024, the accrued vacation obligation was approximately \$88,000 and \$176,000, respectively, and was reported as part of accrued compensation in the accompanying statements of financial position.

#### [9] Grants payable:

Unconditional grants are recognized as an obligation to the Society at the time they are approved. In 2025, the Society awarded grants for 1-year terms. Prior to 2025, multi-year grants were awarded. Payments of multi-year grants are made based on the progress from the grantee that coincides with the satisfactory progression of the project. Multi-year grants payable are reported at their present values, using an appropriate interest rate.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Notes to Financial Statements December 31, 2025 and 2024

### NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### [10] Leases:

The Society determines if an arrangement is a lease at inception. For the Society's operating leases, a right-of-use ("ROU") asset represents the Society's right to use an underlying asset for the lease terms and an operating lease liability represents an obligation to make lease payments arising from the leases. The ROU asset and lease liability are recognized at the lease commencement date based on the present value of lease payments over the lease term. Since the Society's lease agreement does not provide an implicit interest rate, the Society uses a risk-free rate based on the information available at the commencement date in determining the present value of the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs, such as operating costs, are expensed as incurred.

#### [11] Net assets:

(i) *Net assets without donor restrictions:*

Net assets without donor restrictions represent those resources for which there are no restrictions by donors as to their use and are, therefore, available for current operations.

The Society has designated a portion of net assets to function as a reserve to be spent at the discretion of the Board.

(ii) *Net assets with donor restrictions:*

Net assets with donor restrictions represent those resources that are subject to donor-imposed restrictions, such as specific purposes and/or a specific period of time. Also included within net assets with donor restrictions are donor restrictions that are perpetual in nature and subject to the requirements of the New York Prudent Management of Institutional Funds Act ("NYPMIFA"). These donors have stipulated that those resources be maintained in perpetuity with the resultant income and net capital appreciation arising from the underlying assets to be used in satisfaction of the wishes of those donors. When a donor restriction expires, that is, when a stipulated time restriction ends, or a purpose restriction is accomplished, or funds are appropriated through an action of the Board of Trustees, net assets with donor restrictions are reclassified to net assets without donor restrictions and are reported in the statements of activities as "net assets released from restrictions."

#### [12] Revenue recognition:

(i) *Contributions, grants and bequests:*

Contributions and grants made to the Society are recognized as revenue upon the receipt of cash or other assets, or of unconditional pledges. Contributions and grants are reported as "with donor restrictions" if they are received with donor stipulations or time considerations as to their use. Conditional contributions and grants are recognized when the donor's conditions have been met by requisite actions of the Society's management or necessary events have taken place. The Society records bequest income at the time it has an established right to a bequest and the proceeds are measurable. Contributions to be received over periods longer than a single year are discounted at an interest rate commensurate with the risk involved. The Society assesses the collectability of its receivables and provides for an allowance for anticipated losses, if any, when necessary.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Notes to Financial Statements December 31, 2025 and 2024

### NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### [12] Revenue recognition: (continued)

##### (ii) *Special events:*

Gross proceeds paid by attendees at special events held as fundraising activities represents contribution revenue, as well as the payment of the direct costs of the benefits received by the attendee at the event. Special event income is reported net of the direct benefits to donors. Special event revenues, other than contributions, applicable to a current year are recognized as revenue in the year a special event takes place. Special event revenue received for a future year's event is deferred and recognized when the event takes place.

##### (iii) *Donated services and materials:*

The Society, from time-to-time, receives various forms of gifts-in-kind, which are contributions of nonfinancial assets, including pro-bono legal services, auction items and donated space. These types of contributions are reported at their estimated fair value on the date of receipt and reported as expenses when utilized. Gifts-in-kind are valued based upon estimates of fair value or wholesale values that would be received for selling the goods in their principal marketplace considering their condition and utility for use at the time the goods are contributed by the donor. Contributions of nonfinancial assets, other than auction items are not sold, and goods are only distributed for program and fundraising purposes. Auction items are monetized as part of fundraising events. For recognition of donated services, such services must (i) create or enhance non-financial assets, (ii) typically need to be acquired, if not provided by donation, (iii) require a specialized skill, and (iv) be provided by individuals possessing these skills.

#### [13] Functional allocation of expenses:

The costs of providing the Society's various programs and supporting services have been summarized on a functional basis in the statements of activities. The statements of functional expenses present expenses by natural classification and function. Accordingly, direct costs have been functionalized within the program and supporting services, based on the nature of each expense. Indirect costs have been allocated on the basis of time allocation with the exception of rent, insurance, and depreciation, which are allocated based on utilization.

#### [14] Income tax uncertainties:

The Society follows the provisions of the Financial Accounting Standards Board ("FASB") Accounting Standard Codification ("ASC") Topic 740, *Income Taxes*, as it relates to accounting and reporting for uncertainty in income taxes. Because of the Society's general tax-exempt status, management believes ASC Topic 740 has not had, and is not anticipated to have, a material impact on the Society's financial statements.

#### [15] Measure of operations:

The Society includes in its definition of operations all revenues and expenses that are an integral part of its programs and supporting activities. Non-operating activities include returned grant funds.

#### [16] Reclassification:

Certain information in the prior year's financial statements was reclassified to conform to the current year's presentation.

#### [17] Subsequent events:

The Society evaluated subsequent events through April 17, 2026, the date on which the financial statements were available to be issued.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Notes to Financial Statements December 31, 2025 and 2024

### NOTE B - PLEDGES AND CONTRIBUTIONS RECEIVABLES

At each year-end, pledges and contributions receivable were estimated to be due as follows:

	December 31,	
	2025	2024
Less than one year	\$ 2,166,804	\$ 1,510,514
One to five years	91,648	91,648
	<b>2,258,452</b>	1,602,162
Reduction of pledges due in excess of one year to present value, using discount rate of 4%	<b>(6,044)</b>	(4,124)
Less: allowance for doubtful collections	<b>(27,996)</b>	(30,797)
	<b>\$ 2,224,412</b>	<b>\$ 1,567,241</b>

### NOTE C - INVESTMENTS

ASC Topic 820, *Fair Value Measurements*, establishes a three-level valuation hierarchy of fair-value measurements. These valuation techniques are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. These two types of inputs create the following fair-value hierarchy:

- Level 1: Valuations are based on observable inputs that reflect quoted market prices in active markets for identical investments, at the reporting date.
- Level 2: Valuations are based on: (i) quoted prices for similar investments in active markets; or (ii) quoted prices for identical or similar investments, in markets that are not active; or (iii) pricing inputs other than quoted prices that are directly or indirectly observable at the reporting date.
- Level 3: Valuations are based on pricing inputs that are unobservable and include situations where: (i) there is little, if any, market activity for the investments; or (ii) the investments cannot be independently valued.

The availability of market data is monitored to assess the appropriate classification of financial instruments within the fair-value hierarchy. Changes in economic conditions or valuation techniques may require the transfer of financial instruments from one level to another. In such instances, the transfer is reported at the beginning of the reporting period.

The following tables summarize the fair values of the Society's investments at each year-end, in accordance with the ASC Topic 820 fair-value levels:

	December 31,			
	2025		2024	
	Level 1	Total	Level 1	Total
Money market funds	\$ 528,761	\$ 528,761	\$ 554,736	\$ 554,736
Common stock	10,820	10,820	45,352	45,352
U.S. Treasury bills	3,554,894	3,554,894	2,744,009	2,744,009
Mutual funds	2,650,048	2,650,048	2,159,043	2,159,043
	<b>\$ 6,744,523</b>	<b>\$ 6,744,523</b>	<b>\$ 5,503,140</b>	<b>\$ 5,503,140</b>

## HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

### Notes to Financial Statements December 31, 2025 and 2024

#### NOTE C - INVESTMENTS (CONTINUED)

During each year, investment income consisted of the following:

	December 31,	
	2025	2024
Interest and dividends	\$ 215,523	\$ 149,311
Investment management fees	(20,300)	(20,810)
Realized gains	62,865	55,251
Unrealized gains	14,227	14,983
	<u>\$ 272,315</u>	<u>\$ 198,735</u>

#### NOTE D - PROPERTY AND EQUIPMENT

At each year-end, property and equipment consisted of the following:

	December 31,	
	2025	2024
Computer and equipment	\$ 31,940	\$ 88,502
Furniture and fixtures	120,527	120,527
Leasehold improvements	113,237	152,304
	<u>265,704</u>	<u>361,333</u>
Less: accumulated depreciation and amortization	<u>(135,039)</u>	<u>(198,428)</u>
	<u>\$ 130,665</u>	<u>\$ 162,905</u>

During 2025, the Society disposed of fully depreciated leasehold improvements no longer in use of \$95,629.

#### NOTE E - GRANTS PAYABLE

At each year-end, grants payable are due to be paid as follows:

	December 31,	
	2025	2024
One year or less	\$ 795,024	\$ 560,611
One to five years	142,020	1,213,562
	<u>937,044</u>	<u>1,774,173</u>
Reduction of grants due in excess of one year to present value, at a discount rate of 2.4% - 4%	<u>(7,339)</u>	<u>(26,592)</u>
	<u>\$ 929,705</u>	<u>\$ 1,747,581</u>

During 2025 and 2024, the Society had returned grants totaling \$87,491 and \$113,657, respectively.

## HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

### Notes to Financial Statements December 31, 2025 and 2024

#### NOTE F - EVENT REVENUE RECEIVED IN ADVANCE

The following table provides information about event revenue received in advance as follows:

	Year Ended December 31,	
	2025	2024
Event revenue received in advance, beginning of year	\$ 22,336	\$ 32,349
Revenue recognized that was included in event received in advance, beginning of year	(22,336)	(32,349)
Increase in event revenue received in advance due to cash received during the period	<u>30,053</u>	<u>22,336</u>
Event revenue received in advance, end of year	<u>\$ 30,053</u>	<u>\$ 22,336</u>

There were no other significant contract liabilities or assets at December 31, 2025 and 2024.

#### NOTE G - EMPLOYEE-BENEFIT PLAN

The Society maintains a defined-contribution employee-benefit plan, established under Section 403(b) of the Code. The plan covers all eligible employees. The Society contributes a portion of an eligible employee's salary to the plan. The Society's contributions for 2025 and 2024 were approximately \$122,000 and \$142,000, respectively.

#### NOTE H - BANK LINE OF CREDIT

The Society has a bank line of credit in the amount of \$500,000, which is collateralized by the general assets of the Society. The interest rate is based on SOFR, with a variable rate of 8.56%. There were no draw downs on this line of credit during 2025 or 2024. The line of credit renews annually.

#### NOTE I - IN-KIND CONTRIBUTIONS

In-kind contributions (contributions of nonfinancial assets) consisted of the following:

Category	Type	Valuation	December 31,	
			2025	2024
Rent	Space	Standard industry pricing for similar services/actual costs incurred by contributor	\$ 3,840	\$ 3,840
Legal	Pro-bono	Standard industry pricing for similar services/actual costs incurred by contributor	208,588	2,300
Special events	Auction items	U.S. wholesale priced of identical or similar products	<u>150,245</u>	<u>199,693</u>
			<u>\$ 362,673</u>	<u>\$ 205,833</u>

There were no restrictions on these donated goods and services during 2025 or 2024.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Notes to Financial Statements December 31, 2025 and 2024

### NOTE J - NET ASSETS WITH DONOR RESTRICTIONS

At each year-end, net assets with donor restrictions consisted of the following:

	<b>December 31,</b>	
	<b>2025</b>	<b>2024</b>
Time-restricted for future periods:		
Bequests	\$ -	\$ 25,000
Topper - fellowship	<b>160,527</b>	252,502
Total time-restricted for future periods	<b>160,527</b>	277,502
Purpose restrictions:		
Research	<b>1,779,421</b>	2,609,775
Family services	<b>43,162</b>	121,173
Education	<b>67,646</b>	52,210
Chapter development	<b>54,012</b>	104,012
Total purpose restrictions	<b>1,944,241</b>	2,887,170
Accumulated endowment income subject to appropriation by the Board of Trustees	<b>55,462</b>	38,136
Perpetual in nature	<b>250,000</b>	250,000
	<b>\$ 2,410,230</b>	<b>\$ 3,452,808</b>

During each year, net assets released from restrictions resulted from satisfying the following donor restrictions:

	<b>December 31,</b>	
	<b>2025</b>	<b>2024</b>
Time-restricted:		
HD Cope	\$ 25,000	\$ -
Topper - fellowship	<b>232,975</b>	198,005
Purpose restricted:		
Research	<b>1,114,101</b>	1,340,389
Family services	<b>109,684</b>	247,882
Education	<b>149,626</b>	122,730
Chapter development	<b>50,000</b>	1,000
	<b>\$ 1,681,386</b>	<b>\$ 1,910,006</b>

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Notes to Financial Statements December 31, 2025 and 2024

### NOTE K - ACCOUNTING AND REPORTING FOR ENDOWMENT

#### [1] The endowment:

The Society's endowment consists of one donor-restricted fund, established by the donor for the purpose of funding medical research in the field of Huntington's Disease. As required by U.S. GAAP, net assets associated with the endowment fund are classified and reported based on the existence or absence of donor-imposed restrictions.

#### [2] Interpretation of relevant law:

NYPMIFA is applicable to all of the Society's institutional funds, including its donor-restricted fund. Management of the Society adheres to NYPMIFA's requirements.

#### [3] Changes in endowment net assets with donor restrictions, during each year:

	December 31, 2025		
	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Endowment net assets, beginning of year	\$ 38,136	\$ 250,000	\$ 288,136
Investment gains, net	17,326	-	17,326
Endowment net assets, end of year	<u>\$ 55,462</u>	<u>\$ 250,000</u>	<u>\$ 305,462</u>

	December 31, 2024		
	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Endowment net assets, beginning of year	\$ 33,413	\$ 250,000	\$ 283,413
Investment gains, net	4,723	-	4,723
Endowment net assets, end of year	<u>\$ 38,136</u>	<u>\$ 250,000</u>	<u>\$ 288,136</u>

#### [4] Funds with deficiencies:

Due to unfavorable market fluctuations, from time to time, the fair value of assets associated with individual donor-restricted endowment funds may decline below the historical dollar value of the donor's original gift, or the amount required to be maintained under state law, referred to as underwater endowment. Under the terms of NYPMIFA, the Society has no responsibility to restore such decreases in value. At December 31, 2025 and 2024, there were no deficiencies of this nature.

#### [5] Return objectives and risk parameters:

The Society has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding for programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets and assuming a moderate level of investment risk.

#### [6] Strategies employed for achieving objectives:

To satisfy its long-term, rate-of-return objectives, the Society relies on a total-return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Society targets a diversified asset allocation to achieve its long-term return objectives within prudent risk constraints.

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Notes to Financial Statements December 31, 2025 and 2024

### NOTE K - ACCOUNTING AND REPORTING FOR ENDOWMENT (CONTINUED)

#### [7] Spending policy and relationship to investment objectives:

Management of the Society evaluates its funding requirements on an annual basis and, accordingly, draws from its endowment appreciation on an as-needed and prudent basis. This is consistent with the Society's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term, as well as to provide additional real growth through new gifts and investment returns. In accordance with its policy, management elected to suspend appropriation from its endowment earnings for both 2025 and 2024.

### NOTE L - LEASE AGREEMENTS AND COMMITMENTS

#### [1] Lease agreements:

The Society has an operating lease agreement for office facilities located in New York City. The lease provides for rent increase and escalation charges and will expire on February 28, 2034. The aggregate minimum lease payments were being amortized using the straight-line method over the term of the lease.

The Society is also obligated for certain equipment under an operating lease that expires in August 2028.

Total lease costs under these agreements were \$301,177 and \$290,175 for 2025 and 2024, respectively. There were no variable costs included in the total lease costs for 2025 and 2024.

The table below summarizes the Society's future minimum lease payments under operating leases, including a reconciliation to the discounted amount recorded on the statements of financial position as of December 31, 2025 and 2024 as follows:

Year Ending December 31,	2025	2024
2025	\$ -	\$ 301,177
2026	308,440	308,440
2027	315,884	315,884
2028	319,958	319,958
2029	320,667	320,667
2030	328,684	328,684
Thereafter	1,096,523	1,096,523
Total minimum lease payments	2,690,156	2,991,333
Less: amount representing interest	(428,042)	(528,162)
Lease liability reported on statements of financial position	<u>\$ 2,262,114</u>	<u>\$ 2,463,171</u>
<b>Weighted-average remaining lease term:</b>		
Operating lease	8 years	9 years
<b>Weighted-average discount rate:</b>		
Operating lease	2.12%	2.12%

# HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.

## Notes to Financial Statements December 31, 2025 and 2024

### NOTE L - LEASE AGREEMENTS AND COMMITMENTS (CONTINUED)

#### [2] Employment agreement:

During 2025, the Society entered into an employment agreement with its Chief Executive Officer that will expire on January 31, 2027. This contract is automatically renewed every two years.

### NOTE M - CREDIT RISK

Financial instruments that potentially subject the Society to concentrations of credit risk consist principally of cash and cash-equivalent accounts deposited in high-credit-quality financial institutions, the balances of which, from time to time, may exceed federally insured limits. However, based on the current Federal Deposit Insurance Coverage, management monitors the risk associated with concentrations on an ongoing basis and believes that the Society is not exposed to any significant risk of loss due to the failure of these financial institutions.

### NOTE N - LIQUIDITY AND AVAILABILITY OF RESOURCES

The following reflects the Society's financial assets available for general expenditure (including scheduled grant payments) within one year of the statements of financial position dates, reduced by amounts not available for general use within one year due to donor-imposed restrictions or internal designations:

	<b>December 31,</b>	
	<b>2025</b>	<b>2024</b>
Cash and cash equivalents	<b>\$ 7,230,595</b>	\$ 7,409,235
Pledges and contributions receivable, net	<b>2,224,412</b>	1,567,241
Investments	<b>6,744,523</b>	5,503,140
	<b>16,199,530</b>	14,479,616
Total financial assets available within on year		
Less: amounts unavailable for general expenditures within one year due to:		
Time-restricted for future periods	<b>(160,527)</b>	(277,502)
Purpose restrictions	<b>(1,944,241)</b>	(2,887,170)
Perpetual in nature	<b>(250,000)</b>	(250,000)
	<b>(2,354,768)</b>	(3,414,672)
Subject to appropriation:		
Accumulated endowment income subject to appropriation by the Board of Trustees	<b>(55,462)</b>	(38,136)
Amounts unavailable to management without Board approval:		
Board-operating reserve	<b>(3,558,873)</b>	(3,281,277)
	<b>(5,969,103)</b>	(6,734,085)
Total amounts unavailable for general expenditure within one year		
Total financial assets available to meet cash needs for general expenditures within one year	<b>\$ 10,230,427</b>	\$ 7,745,531

## **HUNTINGTON'S DISEASE SOCIETY OF AMERICA, INC.**

### **Notes to Financial Statements December 31, 2025 and 2024**

#### **NOTE N - LIQUIDITY AND AVAILABILITY OF RESOURCES (CONTINUED)**

##### **Liquidity policy:**

The Society's policy is to structure its financial assets to be available for its general expenditures, liabilities and other obligations as they come due. The Society also has a committed line of credit to help manage unanticipated liquidity needs, if needed. Additionally, the Society has Board-designated net assets without donor restrictions that could be accessed in case of additional unanticipated liquidity needs; however, the Society does not intend to use those funds for purposes other than those identified by the Board of Trustees.